McKesson CorporationNYSE: MCK

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

McKesson is preparing for a major CFO transition with Kenny Cheung set to join as Executive Vice President and CFO effective May 29, succeeding retiring CFO Britt Vitalone. On May 15, an analyst reiterated a Buy rating citing durable growth and biosimilar tailwinds. Citi lowered its price target to $945 from $975 on May 14, while Wells Fargo reaffirmed Hold on May 13. The company recently posted strong FY2026 Q4 results with consolidated revenues of $96.3B (up 6%) and adjusted EPS of $11.69 (up 16%), and authorized an additional $5B share repurchase bringing total authorized to $7.7B. Effective May 1, Brian Tyler was elected Chair of the Board and Dominic J. Caruso became Lead Independent Director. The Apollo $1.25B convertible preferred investment for 13% of the Medical-Surgical Solutions segment is advancing.

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Resultsmckesson.comWill Analyst Revisions And A CFO Transition Reshape McKesson's (MCK) Investment Narrative?simplywall.stMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutionsbusinesswire.com

McKesson reported FY26 Q4 results on May 7 with quarterly revenue of $96.3B (+6%), adjusted EPS of $11.69 (+16%), and full-year adjusted EPS of $39.11 (+18%) above long-range targets. The company entered a $2.25B accelerated share repurchase program and the board authorized an additional $5.0B, bringing total authorized to $7.7B. Brian Tyler was elected Chair effective May 1, and incoming CFO Kenny Cheung takes over May 29. The Apollo Funds deal for a 13% minority interest in Medical-Surgical Solutions (valuing MMS at $13B) progressed. Citi cut its price target to $945 from $975 while UBS raised theirs to $1,050 from $1,000. Shares were $774.47 on May 18.

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Resultsmckesson.comWill Analyst Revisions And A CFO Transition Reshape McKesson's (MCK) Investment Narrative?simplywall.stMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutionsbusinesswire.com

Citi lowered its McKesson price target to $945 from $975 while maintaining a Buy rating, after the May 7 fiscal Q4 2026 print delivered $96.3B in revenue, up 6%, and adjusted EPS of $11.69, up 16% and roughly 1% above consensus. McKesson approved an additional $5.0B share repurchase authorization (bringing total authorization to $7.7B) and entered a $2.25B accelerated share-repurchase program, an aggressive capital-return signal. Effective May 1, Brian Tyler was elected Board Chair and Dominic Caruso became Lead Independent Director, and Kenny Cheung joins as EVP and CFO on May 29, succeeding Britt Vitalone. The previously announced Apollo deal for a ~13% minority stake in Medical-Surgical Solutions remains pending regulatory approval. Why it matters: the larger buyback and reaffirmed long-term growth targets underline confidence in earnings power and capital allocation. The bear case: revenue missed Citi's bar enough to warrant a $30 target cut, leadership turnover in the CFO seat introduces execution risk, and biosimilar/Med-Surg separation timing remains a swing factor.

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidancemckesson.comMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutionsbusinesswire.comMCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives Continuestockstory.org

McKesson reported fiscal Q4 2026 results showing consolidated revenue of $96.3B (+6% YoY but ~5.3% below consensus), GAAP EPS of $13.71 (+$3) and adjusted EPS of $11.69 (+16% YoY, ~1.1% above consensus), pressured by price declines and lower GLP-1 distribution volumes. The board approved an additional $5.0B share buyback bringing total authorization to $7.7B as of April 2026, alongside a $2.25B accelerated share repurchase program. Brian Tyler became Board Chair effective May 1; Kenny Cheung joins as EVP/CFO May 29. Apollo Funds is investing $1.25B in convertible preferred for ~13% of McKesson's Medical-Surgical Solutions unit (valuing MMS at ~$13B). Analyst PT moves: UBS raised to $1,050 (May 8); Citi cut to $945 (May 14); analyst reiterated Buy May 15 citing biosimilar tailwinds. Bear case: revenue miss and ongoing GLP-1 distribution softness signal margin pressure if specialty growth slows.

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Resultsmckesson.comMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutionsbusinesswire.comMCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives Continuestockstory.org

McKesson reported FY26 Q4/full-year results May 13 with full-year revenue of $403.4B and adjusted EPS of $39.11 (+16% YoY). Management raised FY27 adjusted EPS guidance to $43.80-$44.60 and announced a $2.25B accelerated share repurchase program. Brian Tyler was elected Board Chair effective May 1, with Kenny Cheung joining as EVP and CFO May 29. McKesson also signed a deal with Apollo Funds for a $1.25B investment for ~13% minority interest in its Medical-Surgical Solutions business, valuing the unit at ~$13B as part of separation/IPO preparation. Multiple analysts adjusted PTs after Q1 results showed a revenue miss: Citi $945 (from $975), UBS $1,050 (from $1,000), Evercore ISI $850 (from $950), Baird $941 (from $1,010), Deutsche Bank $875 (from $973), JPMorgan $1,015 (from $1,107).

McKesson Reports Fiscal 2026 Q4 and Full Year Resultsmckesson.comMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interestbusinesswire.comMcKesson Q4 FY2026 slides: EPS beats amid revenue shortfallinvesting.com

McKesson reported on May 7 fiscal Q4 2026 results with revenue of $96.3 billion (up 6% YoY but missing analyst expectations by 5.5%) and adjusted EPS of $11.69 (up 16%, beating consensus by 1.1%). Full-year revenue reached $403.4 billion (+12%) with adjusted EPS of $39.11 (+18%). The company entered a $2.25 billion accelerated share repurchase and the board approved an additional $5.0 billion buyback authorization, bringing total authorized repurchases to $7.7 billion. Effective May 1, Brian Tyler became Board Chair and Dominic Caruso became Lead Independent Director, with long-time CFO Britt Vitalone retiring and Kenny Cheung taking the CFO role. McKesson participated in the BofA Securities 2026 Healthcare Conference on May 12, and UBS raised its price target to $1,050. The bear case is the revenue miss reflecting weakness in distribution growth plus leadership transition risk during CFO handover.

McKesson Reports Fiscal 2026 Q4 and Full Year Resultsmckesson.comMcKesson Q4 FY2026 slides: EPS beats amid revenue shortfallinvesting.comWill Analyst Revisions And A CFO Transition Reshape McKesson?simplywall.st

McKesson reported fiscal Q4 2026 revenue of $96.3B (+6% YoY) and adjusted EPS of $11.69 (+16%), but revenue missed analyst estimates by ~5.5%. The company issued FY27 adjusted EPS guidance of $43.80-$44.60, implying 12-14% growth. Apollo Global will acquire approximately 13% minority interest in the Medical-Surgical Solutions segment in a $1.25B deal, signaling portfolio optimization. The board authorized an additional $5.0B share repurchase, bringing total authorization to $7.7B. Brian Tyler was elected Chair effective May 1, and Kenny Cheung joins as CFO May 29.

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Resultsmckesson.comMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interestbusinesswire.comMCK Q1 Deep Dive: Revenue Misses Analyst Expectationsstockstory.org

McKesson reported fiscal Q4 2026 results on May 7, 2026 with consolidated revenues of $96.3 billion (up 6% YoY) and adjusted EPS of $11.69 (up 16% YoY, beating consensus by 1.1%). FY27 guidance calls for 7% sales growth and 14% EPS growth. The Board approved an additional $5.0B share repurchase authorization, bringing total to $7.7B, after completing $2.7B repurchases in Q4. Apollo Funds will invest $1.25B in convertible preferred equity for ~13% minority stake in McKesson Medical-Surgical Solutions, valuing the unit at ~$13B. Brian Tyler became Chair effective May 1, with Kenny Cheung joining as EVP & CFO May 29. UBS raised PT to $1,050; multiple analysts cut targets including Evercore ($850), BofA ($900), Deutsche Bank ($875), and JPMorgan ($1,015).

McKesson Reports Fiscal 2026 Q4 and Full Year Resultsmckesson.comMcKesson Signs Agreement with Apollo Funds for Med-Surg Stakebusinesswire.comMCK Q1 Deep Dive: Revenue Misses Analyst Expectationsstockstory.org

On May 7, McKesson reported fiscal Q4 2026 results with consolidated revenue of $96.3B (+6%) and adjusted diluted EPS of $11.69 (+16% YoY). Effective May 1, the Board elected Brian Tyler as Chair and Dominic Caruso as Lead Independent Director, while Kenny Cheung will join as EVP/CFO on May 29. The company entered a $2.25B accelerated share repurchase and added $5.0B to its buyback authorization, bringing total available capacity to $7.7B. UBS raised its price target to $1,050 while Evercore ISI cut to $850 on margin concerns. Risk: Investors remain worried that GLP-1 drug pricing changes could compress drug-distributor margins and pressure FY2027 guidance.

McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Resultsmckesson.comMcKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutionsbusinesswire.comWhy McKesson's Stock Is Slumping Ahead of Earningstipranks.com

McKesson reported fiscal Q4 2026 adjusted EPS of $11.69 (beat $11.57) but revenue of $96.3B missed $101.23B estimate. For FY27, company raised adjusted EPS guidance to $43.80-44.60 (+12-14%). Oncology & Multispecialty segment surged 35% YoY revenue to $12.7B. McKesson signed deal with Apollo Funds for 13% minority stake in Medical-Surgical Solutions for $1.25B. Generated $3.2B free cash flow in quarter; returned $2.7B to shareholders via buybacks.

McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Resultsmckesson.comMcKesson posts Q1 earnings beat, but revenue misses estimatesinvesting.comMcKesson Corporation - Stock Informationinvestor.mckesson.com